- Home
- FLY vs PCVX Comparison
FLY vs PCVX Comparison
Compare FLY & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FLY | PCVX |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 6.1B |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FLY | PCVX |
|---|---|---|
| Price | $19.51 | $54.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | $40.75 | ★ $97.67 |
| AVG Volume (30 Days) | ★ 3.5M | 1.7M |
| Earning Date | 03-22-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $111,216,000.00 | N/A |
| Revenue This Year | $156.28 | N/A |
| Revenue Next Year | $189.66 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 101.35 | N/A |
| 52 Week Low | $16.00 | $27.66 |
| 52 Week High | $73.80 | $86.68 |
Technical Indicators
Market Signals| Indicator | FLY | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 37.58 | 60.95 |
| Support Level | $18.80 | $51.34 |
| Resistance Level | $25.32 | $58.00 |
| Average True Range (ATR) | 2.41 | 3.17 |
| MACD | -0.93 | -0.10 |
| Stochastic Oscillator | 4.52 | 64.44 |
Price Performance
Historical ComparisonAbout FLY Firefly Aerospace Inc.
Firefly Aerospace Inc is a space and defense technology company with an established track record of success providing comprehensive mission solutions to national security, government, and commercial customers. The company enables government and commercial customers to launch, land and operate in space - Anywhere, Anytime.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.